期刊文献+

RET与VEGF—C在甲状腺乳头状癌中表达的研究 被引量:2

Study on expression of RET and VEGF - C in papillary carcinoma of thyroid
下载PDF
导出
摘要 目的探讨RET和VEGF—C在甲状腺乳头状癌发生发展中的作用,以及RET和VEGF—C之间相互作用的关系。方法应用免疫组化二步法检测60例甲状腺乳头状癌和10例正常甲状腺组织中RET蛋白和VEGF—C蛋白的表达情况,分析RET和VEGF—C的蛋白表达率与临床病理学特征之间的关系以及二者表达之间的相关性。结果RET和VEGF—C在甲状腺乳头状癌与甲状腺正常组织中的阳性表达率之间均具有显著性差异(P〈0.05)。RET和VEGF—C与患者的性别、年龄、肿瘤大小无显著差异(P〉0.05)。RET和VEGF—C与患者的颈部淋巴结转移、临床分期有显著差异(P〈0.05)。RET和VEGF—C之间呈正相关(P〈0.05)。结论RET表达在甲状腺乳头状癌淋巴结转移方面具有非常重要作用,其有可能通过调节VEGF—C的表达来促进淋巴结的转移。RET和VEGF—C可作为判断甲状腺乳头状癌淋巴结转移的可能指标。 Objective To investigate the expression of RET and VEGF - C in papillary carcinoma of thyroid, Soasto the role and correlation of RET and VEGF - C. Methods Detecting the expression of RET and VEGF - C in 60 papillary carcinoma of thyroid tissues and 10 normal thyroid tissues by immunohistoche mical Envision two - step method, analyzing the correlation between the protein expression rate and clinical and pathological characters,and also the correlation between the expression of RET and VEGF - C. Results Expression of every oncogene was significantly different between papillary carcinoma of thyroid tissues and normal thyroid tis- sues( P 〈0.05 ). The positive expression rate of RET and VEGF- C were significantly associated with cervical lymph node metastasis and clinical stages( P 〈0.05 ) , but not associated with sex, age, primary site of the tumor ( P 〉 0.05 ). The positive expression of RET closely related to the positive expression of VEGF - C ( P 〈 0.05 ). Conclusion The results demonstrate that RET may play an important role in the cervical lymph node metastasis of papillary carcinoma of thyroid,the expression of VEGF - C. RET and VEGF - C should be used as an important marker of cervical lymph node metastasis.
出处 《实用肿瘤学杂志》 CAS 2010年第4期373-377,共5页 Practical Oncology Journal
基金 哈尔滨市科委青年攻关基余资助项目(2006RFOX086)
关键词 甲状腺乳头状癌 RET VEGF—C 免疫组织化学 Papillary Carcinoma of the Thyroid RET VEGF - C Immunohistochemistry
  • 相关文献

参考文献9

  • 1Nikiforov E.RET/PTC rearrangement in thyroid tumors[J].Endocr Pathol,2002,13(1):3-16.
  • 2郑荣秀,方佩华,吕枚.甲状腺乳头状癌患者ret基因重排突变[J].中华内分泌代谢杂志,2005,21(2):106-109. 被引量:9
  • 3Kondo T,Ezzat S,Asa SL.Pathogenetic mechanism in thyroid follicular-cell neoplasia[J].Nature Rev Cancer,2006,6(4):292-306.
  • 4王翠芳,孙洁,滕猛,宦大为.RET、HBME-1和Ki67在甲状腺良、恶性肿瘤中的表达[J].实用肿瘤学杂志,2007,21(5):427-429. 被引量:3
  • 5Hamatani K,Eguchi H,Ito R,et al.RET/PTC rear rangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose[J].Cancer Res,2008,68(17):7176-7718.
  • 6王伟,朱建伟,马利林.氧化应激环境下大肠癌细胞VEGF转录活性的变化[J].实用肿瘤学杂志,2007,21(1):5-8. 被引量:2
  • 7Jennbacken K,Vallbo C,Wang W,et al.Expression of vascular endothelial growth factor C(VEGF-C)and VEGF receptor-3 in human prostate cancer associated with regional lymph nodemetastasis[J].Prostate,2005,65(2):110-116.
  • 8Tian X,Cong M,Zhou W.Relationship between protein expression of VEGF-C,MMP-2 and lymph node metastasis in papillary thyroid cancer[J].J Int Med Res,2008,36(4):699-703.
  • 9Yu XM,Lo CY,Lam AK.Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma[J].Ann Surg,2008,47(3):483-489.

二级参考文献36

  • 1白耀.甲状腺恶性肿瘤诊断和治疗的热点讨论[J].中华内分泌代谢杂志,2004,20(4):283-286. 被引量:19
  • 2顾丽群,赵咏桔,马晓,章英剑,赵红燕,戴蒙,王丽华,张连珍,赵列宾,宁光.甲状腺髓样癌患者RET原癌基因突变的研究[J].中华内分泌代谢杂志,2004,20(4):287-288. 被引量:8
  • 3吴胤瑛,李恩孝.VEGF在恶性肿瘤中的研究进展[J].现代肿瘤医学,2005,13(5). 被引量:56
  • 4张军,吴毅平.结肠癌患者血清IGF-1水平及癌组织VEGF表达的临床意义[J].华中科技大学学报(医学版),2006,35(2):221-223. 被引量:14
  • 5谭郁彬.甲状腺肿瘤和瘤样病变[A].王德延.肿瘤病理诊断学[C].天津科学技术出版社,1999.1565-1570.
  • 6Tallini G. Molecular pathobiology of thyroid neoplasms. Endocr Pathol, 2002,13:271-288.
  • 7Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol, 2002;13:3-16.
  • 8Fusco A, Grieco M, Santoro M, et al. A new oncogene in human thyroid papillary carcinomas and their lymph nodal metastases. Nature, 1987,328:170-172.
  • 9Bongarzone I, Monzini N, Borrello MG, et al. Molecular characte-rization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine-kinase and the regulatory subunit RIα of cyclic AMP-dependent protein kinase A. Mol Cell Biol, 1993,13:358-366.
  • 10Santoro M, Dathan NA, Berlingieri MT, et al.Molecular charac-terization of RET/PTC 3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene, 1994,9:509-516.

共引文献11

同被引文献45

  • 1Takahashi M, Ritz J, Cooper GM. Activation of a novel hu- man transforming gene ret by DNA rearrangement [ J ]. Cell, 1985,42(2) :581 -588.
  • 2Pasini B, Hofstra RM, Yin L, et al. The physical map of the human RET proto - oncogene [ J ]. Oncogene, 1995,11 ( 9 ) : 1737 - 1741.
  • 3Daniela Califano D, Rizzo CD,Alessio A, et al. Signaling through Ras is essential' for Ret oncogene - induced cell dif- ferentiation in PCI2 cells[ J]. J Biol Chem,2000,275 (25) : 19297 - 19305.
  • 4Mai KT, Lanary DC, Thomas J, et al. Ret oncogene protein expression in papillary thyroid carcinoma and related lesions [ J ]. Tumor,2001,87 ( 3 ) : 166 - 172.
  • 5Besset V, Scott RP, Ibanez CF, et al. Signaling complexes and protein - protein interactions involved in the activation of the Ras and phosphatidylinositol 3 - kinase pathways by the c- Ret receptor tyrosine kinase[ J]. J Biol Chem,2000, 275 (50) :39159 - 39164.
  • 6Plaza - Menacho I, Burzynski GM, de Groot JW, et al. Cur- rent concepts in RET - related genetics, signaling and thera- peutics[ J]. Trends Genet,2006,22( 11 ) :627 - 636.
  • 7Iwashita T, Kato M, Murakami H, et al. Biological and bio- chemical properties of Ret with kinase domain mutations i- deniified in multiple endocrine neoplasia type 2B and famil- ial medullary thyroid carcinoma [ J ]. Oncogene, 1999, 18 (26) :3919 - 3922.
  • 8Esseghir S, Todd SK, Hunt T, et al, A role for glial cell de- rived neurotrophic factor induced expression by inflamma- tory cytokines and RET/GFR alpha 1 receptor up - regula- tion in breast cancer [ J ]. Cancer Res, 2007,67 ( 24 ) : 11732 - 11741.
  • 9Borrello MG, Alberti L, Arighi E, et al. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a Docking site for phospholipase C gamma[ J]. Mol Cell Biol, 1996, 16(5) :2151 -2163.
  • 10Kang J, Qian PX, Pandey V, et al. Artemin is estrogen reg- ulated and mediates antiestrogen resistance in mammary carcinoma [ J ]. Oncogene ,2010,29 (22) : 3228 - 3240.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部